BAP1 and intrahepatic cholangiocarcinoma: The patient is still being treated with olaparib and no significant toxicity has been reported.<h4>Conclusion</h4>These findings have clinical relevance since we have shown PARP inhibitor as a potential treatment for ICC patients harboring BAP1 deletion and RAD21 amplification.